The company’s TRPV1 antagonist looks doomed.
ApexOnco Front Page
Recent articles
First human data on MK-2010 are imminent.
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The conference’s abstract drop features ASC4First in its plenary session.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.